top of page
Search

BREAKER-101 trial - Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors

“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumor”

 

Sponsor TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Study Start: October 2024

No locations listed

 

TRIAL LINK: NCT06625775

 

NOTE: All interventional trials involve risk. 

So please consult with your oncology team as well as ask questions of the trial researchers.

 

RAS Initiative update: Taking our drugs to the clinic

July 2024

Slides 13 – 23- The Role of RAS-PI 3’ kinase in cancer

 

 

 

San Antonio Breast Cancer Conference – December 2023

Mini Oral Abstracts – Pedro J. Beltran, PhD

video presentation starts at 7 minutes

 

 

San Antonio Breast Cancer Conference

Slides from Bridge Bio scientific presentations



Black capitalized text that reads, "Revolution Medicine."
Blue capitalized text on a gray background. Text reads, "Amgen."
Genentech_Logo.png_dark blue text that reads, "Genetech." Gray italicized text that reads, "a member of the Roche Group."
Dark blue text on top of sea foam text. Text reads, "Verastem Oncology."
bottom of page